These findings suggest that the treatment with alogliptin has no effects on obesity, hyperglycemia, and plasma Fgf21 levels in individually housed KKAy mice, whereas the treatment with liraglutide reduces the obesity and hyperglycemia independently of plasma active GLP-1 levels. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.